Prevention of long COVID: progress and challenges
- PMID: 37156258
- PMCID: PMC10162711
- DOI: 10.1016/S1473-3099(23)00287-6
Prevention of long COVID: progress and challenges
Conflict of interest statement
I report receiving consultation fees from Gilead Sciences and Tonix pharmaceuticals. I also report consulting (uncompensated) for Pfizer; I have no other relationships or activities that could appear to have influenced the submitted work. This Comment was funded by the US Department of Veterans Affairs (to ZAA). The contents do not represent the views of the US Department of Veterans Affairs or the US government.
References
-
- Uehara T, Yotsuyanagi H, Ohmagari N, et al. Ensitrelvir for mild-to-moderate COVID-19: phase 3 part of phase 2/3 study. https://www.shionogi.com/content/dam/shionogi/global/investors/ir-librar...
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
